

Figure 1






Figure 2



662T30"4T52E60

FIGURE 3



662780 453460




FIGURE 4(a)





FIGURE 4(b)

FIGURE 5



662750" HT52E60




FIGURE 6(a)




FIGURE 6(b)

FIGURE 7





FIGURE 8A



662780" 1133460

FIGURE 8B




FIGURE 8C




FIGURE 9

% of Control (Mean \pm S.E.)






FIGURE 10A



09376544, 091799

Cells/well (Mean \pm S.E.) ($\times 10^{-4}$)






FIGURE 10B

Effects of MP/PO chimeric oligos on DOHH2 cell growth




FIGURE 11

Effects of MP/POchimer. oligos on MCF7 breast carcinoma cell line.




FIGURE 12




FIGURE 13

As72
5'-AGCGCGCGCGCGCAGCGC-3'
Sc72
5'-GGCGCGGGAAGGGCGCGCGC-3'

As23
5'-GCGCGCGCGCGCGCGCA-3'
Sc23
5'-GGCGGAGCGCGCGCGCGG-3'

As-18' mer
5'-TCTCCAGCGTGCGCCAT-3'
Sc-18' mer
5'-TGCACTCAGCTCGGCCT-3'